Anti-CRLF2 Antibody-Armored Biodegradable Nanoparticles for Childhood B-ALL

about

Anti-CRLF2 Antibody-Armored Biodegradable Nanoparticles for Childhood B-ALL

Item

http://www.wikidata.org/entity/Q37102970

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Anti-CRLF2 Antibody-Armored Biodegradable Nanoparticles for Childhood B-ALL

@en

Anti-CRLF2 Antibody-Armored Biodegradable Nanoparticles for Childhood B-ALL.

@nl

type

Item

label

Anti-CRLF2 Antibody-Armored Biodegradable Nanoparticles for Childhood B-ALL

@en

Anti-CRLF2 Antibody-Armored Biodegradable Nanoparticles for Childhood B-ALL.

@nl

prefLabel

Anti-CRLF2 Antibody-Armored Biodegradable Nanoparticles for Childhood B-ALL

@en

Anti-CRLF2 Antibody-Armored Biodegradable Nanoparticles for Childhood B-ALL.

@nl

P1476

Anti-CRLF2 Antibody-Armored Biodegradable Nanoparticles for Childhood B-ALL

@en

P2093

Colleen M Witt

http://www.w3.org/2001/XMLSchema#string

German P Villa

http://www.w3.org/2001/XMLSchema#string

Jonathan A L Gelfond

http://www.w3.org/2001/XMLSchema#string

Kranthi Kancharla

http://www.w3.org/2001/XMLSchema#string

Preethi Janardhanan

http://www.w3.org/2001/XMLSchema#string

Rekha Raghunathan

http://www.w3.org/2001/XMLSchema#string

Robert L Cook

http://www.w3.org/2001/XMLSchema#string

Robert Nadeau

http://www.w3.org/2001/XMLSchema#string

Swetha Mahesula

http://www.w3.org/2001/XMLSchema#string

William E Haskins

http://www.w3.org/2001/XMLSchema#string

P2860

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines

Role of CD47 as a marker of self on red blood cells

Role of CD47 in erythroid cells and in autoimmunity

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Class prediction models of thrombocytosis using genetic biomarkers.

Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.

Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia

Drug transport to brain with targeted nanoparticles.

Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma

P304

355-364

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PPSC.201200125

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Thomas G Forsthuber

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256101513

http://www.w3.org/2001/XMLSchema#string

P698

23976822

http://www.w3.org/2001/XMLSchema#string

P921

biodegradation

P932

3746557

http://www.w3.org/2001/XMLSchema#string